April Powers - Academia.edu (original) (raw)

Related Authors

Erik Hammerstrom

Paul Hedges

Paul Hedges

S Rajaratnam School of International Studies

Michael Radich

Frank Usarski

Neena Mahadev

Årstein Justnes

Klaas Spronk

Klaas Spronk

Protestant Theological University, The Netherlands

Michael Stausberg

rudolph bauer

Imre Hamar

Uploads

Papers by April Powers

Research paper thumbnail of A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection

The Journal of Infectious Diseases, 2004

Research paper thumbnail of In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients

Journal of Clinical Investigation, 2005

Research paper thumbnail of Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection

AIDS, 2006

Objective: To examine the effect of repeated, long-cycle structured intermittent versus continuou... more Objective: To examine the effect of repeated, long-cycle structured intermittent versus continuous HAART on health-related quality of life (HRQL) and symptom distress in patients with chronic HIV infection and plasma HIV RNA of less than 50 copies/ml. Design: Prospective survey of adult patients (n ¼ 46) enrolled in a randomized clinical trial evaluating intermittent versus continuous HAART on immunological and virologic parameters. Patients (n ¼ 23) randomized to structured intermittent therapy received serial cycles of 4 weeks on/8 weeks off HAART. Outcome measures: HRQL was measured by the physical and mental health summary scores of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Symptom distress was measured by the Symptom Distress Scale. Patients completed initial questionnaires prior to randomization and at weeks 4, 12, and 40 of the trial via a touch screen computer in an outpatient clinic. Results: Baseline demographic and clinical characteristics were equivalent in both treatment groups. Although the mental health summary score declined significantly over time for the structured intermittent group, linear mixed modeling ANOVA indicated no significant difference across time for MOS-HIV summary and Symptom Distress Scale scores between the two treatment arms. In this small sample, repeated long-cycle structured intermittent therapy may not provide HRQL or symptom distress advantage compared to continuous HAART in patients with chronic HIV infection over 10 months of treatment. Further research in a heterogenous chronic HIV population and longer follow-up period is warranted.

Research paper thumbnail of Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters

The Journal of Infectious Diseases, 2003

Research paper thumbnail of A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection

The Journal of Infectious Diseases, 2004

Research paper thumbnail of In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients

Journal of Clinical Investigation, 2005

Research paper thumbnail of Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection

AIDS, 2006

Objective: To examine the effect of repeated, long-cycle structured intermittent versus continuou... more Objective: To examine the effect of repeated, long-cycle structured intermittent versus continuous HAART on health-related quality of life (HRQL) and symptom distress in patients with chronic HIV infection and plasma HIV RNA of less than 50 copies/ml. Design: Prospective survey of adult patients (n ¼ 46) enrolled in a randomized clinical trial evaluating intermittent versus continuous HAART on immunological and virologic parameters. Patients (n ¼ 23) randomized to structured intermittent therapy received serial cycles of 4 weeks on/8 weeks off HAART. Outcome measures: HRQL was measured by the physical and mental health summary scores of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Symptom distress was measured by the Symptom Distress Scale. Patients completed initial questionnaires prior to randomization and at weeks 4, 12, and 40 of the trial via a touch screen computer in an outpatient clinic. Results: Baseline demographic and clinical characteristics were equivalent in both treatment groups. Although the mental health summary score declined significantly over time for the structured intermittent group, linear mixed modeling ANOVA indicated no significant difference across time for MOS-HIV summary and Symptom Distress Scale scores between the two treatment arms. In this small sample, repeated long-cycle structured intermittent therapy may not provide HRQL or symptom distress advantage compared to continuous HAART in patients with chronic HIV infection over 10 months of treatment. Further research in a heterogenous chronic HIV population and longer follow-up period is warranted.

Research paper thumbnail of Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters

The Journal of Infectious Diseases, 2003

Log In